Remission of disseminated cancer after systemic oncolytic virotherapy - Wikidata - awgldk - TriplyDB

Remission of disseminated cancer after systemic oncolytic virotherapy

Remission of disseminated cancer after systemic oncolytic virotherapy

http://www.wikidata.org/entity/Q34420326

about

Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccination Oncolytic virus therapy: A new era of cancer treatment at dawn Oncolytic Viruses: Therapeutics With an Identity Crisis Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?Immune Modulation in Hematologic Malignancies Oncolytic virotherapy for human malignant mesothelioma: recent advances Chemovirotherapy: combining chemotherapeutic treatment with oncolytic virotherapy Sensitivity of human pleural mesothelioma to oncolytic measles virus depends on defects of the type I interferon response.Measles to the Rescue: A Review of Oncolytic Measles Virus Trial Watch-Oncolytic viruses and cancer therapy The use of the NIS reporter gene for optimizing oncolytic virotherapy MicroRNA-Detargeted Mengovirus for Oncolytic Virotherapy Nuclear reprogramming with a non-integrating human RNA virus.A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma Infections and cancer: the "fifty shades of immunity" hypothesis.Positive radionuclide imaging of miRNA expression using RILES and the human sodium iodide symporter as reporter gene is feasible and supports a protective role of miRNA-23a in response to muscular atrophy Viral oncolysis - can insights from measles be transferred to canine distemper virus?Oncolytic viruses: From bench to bedside with a focus on safety.Portrait of Dr Michael G. Hanna, Jr. A pioneer in active specific immunotherapy of cancer.In vivo anti-metastatic effects of uPAR retargeted measles virus in syngeneic and xenograft models of mammary cancer Human vaccines & immunotherapeutics: news Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer.Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia.Oncolysis by paramyxoviruses: preclinical and clinical studies.Inhibition of the Aurora A kinase augments the anti-tumor efficacy of oncolytic measles virotherapy.Deficiency of caspase 3 in tumor xenograft impairs therapeutic effect of measles virus Edmoston strain.Oncolytic measles virus efficacy in murine xenograft models of atypical teratoid rhabdoid tumors How to develop viruses into anticancer weapons.A measles virus selectively blind to signaling lymphocytic activation molecule shows anti-tumor activity against lung cancer cells.Newcastle Disease Virus: Potential Therapeutic Application for Human and Canine Lymphoma.Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases.The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment Reporter gene imaging identifies intratumoral infection voids as a critical barrier to systemic oncolytic virus efficacy.Assessment of current virotherapeutic application schemes: "hit hard and early" versus "killing softly"?Enhancing the Tumor Selectivity of a Picornavirus Virotherapy Promotes Tumor Regression and the Accumulation of Infiltrating CD8+ T Cells.Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia.Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques Enhanced lysis by bispecific oncolytic measles viruses simultaneously using HER2/neu or EpCAM as target receptors

P2860

Q26700080-11B74210-95FB-4438-9974-187FFB49E482 Q26739714-FCB42F77-B7B2-4B53-A5E8-E0B92D3DEB87 Q26741020-201F860C-3A86-41EB-BE7A-036D2C61FFF9 Q26752807-C07996DD-7D30-400A-A737-E2F9C3BAC8F5 Q26775030-36E91F39-94C9-4EA2-B255-3F410F97B48D Q26796307-35D77DD1-3C09-4801-81C6-FB7A919185D0 Q26826590-C3050AEC-B536-414B-9D8F-5295FD943B53 Q26852345-781C36ED-4C1E-4C4C-9AF3-ACF78F796312 Q27340224-02F43926-8E07-48CD-8E18-29868005D607 Q28072097-CAEF93DC-1B92-4377-8373-D21B17DB3CA4 Q28072347-DAAD4F6C-61F0-4B0F-9F73-F669F3DECADB Q28083534-E5295E86-9FBB-4C07-9C54-FA984FC024FB Q28601803-54329587-A999-43CD-86E5-F99ADDECDCAD Q30645806-E72AA2A2-F732-48FE-9C83-1C4A361C8097 Q33418048-F48FF037-B2A4-49F3-A9F0-105A09CDCB6F Q33441321-0D9FFA6E-05BC-4E4F-898D-ACEE738ACC33 Q33555975-9D1689F2-8097-4BC3-9431-0B91388C05DE Q33664375-91366824-7D5F-491E-81B5-33AD598C1D8F Q33820717-A9DAF6F9-2D44-4AD7-A7B7-88CDA03BDE05 Q34044071-9988CA1E-61D3-436A-A746-60BF4078AFAA Q34291168-067E47BD-45FE-49C1-B5E8-91BE4B79D217 Q34997475-1D2F1B38-8BA2-4782-839E-E7477687D2B4 Q35208009-0BA31DEB-A999-4DDD-B072-73627453670B Q35226511-24BF7ACF-91D5-456C-9868-E7782398097E Q35812675-29D8E42D-3FC4-4A61-8DF4-93CC06785829 Q35861933-6210E47B-A27D-419D-913A-D35C058E8575 Q36108892-D744C184-9680-4C12-8A84-C8834B69DC65 Q36140704-32A7E96B-0E68-4646-A19E-1D8F8DBF5751 Q36250723-CF81C01D-2DA2-4FF9-9F93-03B9A89F78FE Q36310887-C0428CDC-DA22-45C1-BD62-B52E0432E807 Q36413058-B61366A2-4351-485A-90E6-2CB1C7AED763 Q36507259-CB68EDC4-0FD7-47F0-A72B-6A8807717132 Q36544212-F452182A-FC8A-4752-A0A2-AB39FA9D38CA Q36658280-70A87E6B-529F-4F51-83AC-AFE9EDF20906 Q36664219-819F2620-CE9D-49C2-A030-99133857C356 Q36664268-B2428045-4D11-450A-9CBD-0CFDEEF18816 Q36665114-A29276C0-E04B-4573-9EBE-73B757B6E59C Q36700481-11EB7BC5-911E-4790-A7C1-7E8707A6CECE Q36756690-062387A6-133F-49ED-B02F-AACC29D78CE0 Q36777139-C3B65147-F4B2-4112-BE48-F4D2F20A5B81

P2860

Remission of disseminated cancer after systemic oncolytic virotherapy

http://www.wikidata.org/entity/Q34420326

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Remission of disseminated cancer after systemic oncolytic virotherapy

@ast

Remission of disseminated cancer after systemic oncolytic virotherapy

@en

Remission of disseminated cancer after systemic oncolytic virotherapy

@nl

type

label

Remission of disseminated cancer after systemic oncolytic virotherapy

@ast

Remission of disseminated cancer after systemic oncolytic virotherapy

@en

Remission of disseminated cancer after systemic oncolytic virotherapy

@nl

prefLabel

Remission of disseminated cancer after systemic oncolytic virotherapy

@ast

Remission of disseminated cancer after systemic oncolytic virotherapy

@en

Remission of disseminated cancer after systemic oncolytic virotherapy

@nl

P1433

Q34420326-BF47F6B9-95E4-4C2B-A167-37630A73AF30

P1476

Q34420326-0ABB3476-5E57-473A-8BEE-BE5296C2E40D

P2093

Q34420326-02661DD9-D24C-48A9-9B05-9D49C8631FED

Q34420326-3026ACC6-77D6-4360-BA63-4C06AFF0759B

Q34420326-5C89AE3E-5631-41A8-8188-20357907580B

Q34420326-9449ECCD-2211-4C50-B794-62AF34B89554

Q34420326-98D3F4B2-DF51-49D4-A4FF-1F9DB2AA31ED

Q34420326-C523E9F7-5D45-457A-B05D-9A09D4396F09

Q34420326-D0AD1A3A-5696-4101-B57C-D1C658DA2F6E

P2860

Q34420326-058E7B05-87C0-4BCF-A473-DB3341ACE8C9

Q34420326-09069704-A059-4440-8EDD-95B9F49B503B

Q34420326-11E7719C-5B9B-4442-9730-65E2E3349A13

Q34420326-15B40785-7342-4ABF-8DC9-FDDF5FB10A57

Q34420326-162FDB73-48E7-4864-8D38-64F5F1D0909D

Q34420326-206EC94F-4753-4583-9BB1-10FD3ACC5251

Q34420326-369089EC-028F-41D9-BA57-3345B94DF50E

Q34420326-5529DD59-E11C-4449-AEA5-D606B180FDF6

Q34420326-660D65B0-EE94-436F-8F9C-5B45B27ED692

Q34420326-685559FF-0337-4DFB-9E4F-C9B89EA4E30E

P304

Q34420326-67749C74-2064-42B7-82B4-BF8CF5844E5D

P31

Q34420326-C9A8F4AD-B4BD-4E4F-BAF5-BE82950249A6

P356

Q34420326-1CFF6AB1-D692-4BCF-9AA5-9185F86A15DA

P407

Q34420326-2C0FB6AC-D697-4A81-97B1-5077C62E327E

P433

Q34420326-3DDC1EC8-04E4-4B23-BDAE-5F76245977CA

P478

Q34420326-872794F8-74EC-4CB5-9C13-8AF9BC4BA9AC

P50

Q34420326-02635397-947B-4D8F-8237-9493FC0F43CC

Q34420326-442B914F-2AB9-4D40-951D-8B499DAB0A48

Q34420326-7F4D37E7-A1BC-4449-924C-02BB53905934

Q34420326-8CCB445D-A2F2-4AFA-BFD5-0AC0A5677B2D

Q34420326-A10A7D7E-215D-4925-9578-4E1CB5E8F6B2

Q34420326-B9E3A758-C40D-4609-A21E-3130BDDB7763

Q34420326-F682581F-A3ED-4E2E-9D8C-46CD486A4D4F

Q34420326-F9159B9A-E228-4647-AC7C-529A783A533B

P577

Q34420326-CCA4528D-3B2F-4265-AA83-53830AC29618

P5875

Q34420326-E0FB6CBB-1147-43FE-8798-6B7CA312CC45

P698

Q34420326-7EC0076C-FA1A-4A6F-BEF6-86ED159B41B5

P921

Q34420326-47725867-B880-4569-9856-2310D6109952

P932

Q34420326-087F290E-7B41-4DBA-8EAD-DE7627B20E08

P356

J.MAYOCP.2014.04.003

P1433

Mayo Clinic Proceedings

P1476

Remission of disseminated cancer after systemic oncolytic virotherapy

@en

P2093

Caili Tong

http://www.w3.org/2001/XMLSchema#string

Francis K Buadi

http://www.w3.org/2001/XMLSchema#string

Mark J Federspiel

http://www.w3.org/2001/XMLSchema#string

Michael K O'Connor

http://www.w3.org/2001/XMLSchema#string

Nelson Leung

http://www.w3.org/2001/XMLSchema#string

Val Lowe

http://www.w3.org/2001/XMLSchema#string

William G Morice

http://www.w3.org/2001/XMLSchema#string

P2860

Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers.

Oncolytic viruses for induction of anti-tumor immunity.

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.

Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter.

The combination of immunosuppression and carrier cells significantly enhances the efficacy of oncolytic poxvirus in the pre-immunized host.

Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.

Potent oncolytic activity of human enteroviruses against human prostate cancer.

Mathematical model for radial expansion and conflation of intratumoral infectious centers predicts curative oncolytic virotherapy parameters.

P304

926-933

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.MAYOCP.2014.04.003

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

89

http://www.w3.org/2001/XMLSchema#string

P50

Angela Dispenzieri

Stephen J Russell

S. Vincent Rajkumar

P577

2014-05-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262456814

http://www.w3.org/2001/XMLSchema#string

P698

24835528

http://www.w3.org/2001/XMLSchema#string

P921

oncolytic virus

P932

4225126

http://www.w3.org/2001/XMLSchema#string